Fierce Biotech Names AbCellera a “Fierce 15” Company of 2020
AbCellera Wins Fast Company’s Innovative Team of the Year Award and Is Named to the 2020 Best Workplaces for Innovators List
AbCellera Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2020
AbCellera named one of Canada’s Top Growing Companies
LifeSciences BC Growth Stage Company of the Year Awarded to AbCellera
AbCellera Named to 2016 Life Science Emerging Rockets List of High Growth Companies
Although the natural immune repertoire is a boundless source of therapeutic antibodies, merely sampling from it will not capture its full diversity. Maia Smith, co-creator of AbCellera’s proprietary data visualization tool Celium™ presented “Visualize scale and diversity in natural antibody discovery”. Celium™ is an intuitive and interactive software that visualizes antibodies discovered on AbCellera’s platform, and not only sorts them by clonal ties, functionality, and developability, but relates them to similar antibody sequences in our repertoire.
Watch Maia’s talk here.
AbCellera has successfully completed several antibody discovery programs targeting GPCRs and ion channels. Marta presented insights on AbCellera’s innovative approach in her talk “Against Nature: How to Hack Immune Systems to Discover Antibodies that Target Complex Membrane Proteins”
Using clever immunization strategies and screening millions of single B cells, AbCellera has found and validated hundreds of ultra-low frequency and highly diverse antibodies. Senior Research Scientist, Christopher Williamson presented “Ultra-rare but there: natural and diverse antibodies against high homology targets” in the Protein Engineering stream at this year’s Festival of Biologics.
The Blakes Breakfast Speaking Series is LifeSciences BC’s longest-standing event series, bringing together local, national and multinational life science companies. This month, a panel of speakers contributed to a discussion themed “Understanding the COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19 virus and how BC is leading the fight”. Senior Research Scientist Kathryn Westendorf presented AbCellera’s efforts in her talk “Making an Antibody-Based Therapeutic in 60 Days: High-Throughput Discovery Applied to a Rapid Pandemic Response Platform”.
Co-founder, Véronique Lecault, will be addressing Metro Vancouver’s postdoctoral research community and presenting exciting career opportunities at AbCellera.
Co-founder and Head of Business Development, Kevin Heyries, Ph.D. will be presenting “From Patient Screen to Phase I in 90 Days: Identifying Neutralizing Antibodies for the World’s First Study of a Potential COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19 Antibody Treatment”, in the Making Antibodies Rapidly to Combat Pandemic Viruses session on Tuesday, June 23, 2020.
AbCellera will be at BIO Digital 2020. If you are in the business of biologics, we are looking forward to connecting. Find out how our full technology stack can streamline and accelerate your lead generation. Get in touch via the BIO Portal or email us.
Sherie will be presenting on “Amplifying antibody diversity: Single-cell screening combined with immune repertoire sequencing from humanized mice”.
AbCellera’s co-founder and Head of Business Development, Kevin Heyries, Ph.D., will be presenting ‘Amplifying antibody diversity with Single-cell screening and immune repertoire sequencing’.
High throughput single-cell screening is enabling the rapid generation of large, diverse antibody sequence datasets. By combining immune repertoire sequencing with functionally validated single-cell data, we further expand antibody diversity accessible for lead identification. Celium™, AbCellera’s interactive software, interprets these complex datasets using dynamic visual networks to guide the selection of valuable antibodies. This unparalleled ability to both generate and visualize highly curated large datasets dramatically expands the pool of potential therapeutic candidates.
Kevin Heyries, Ph.D., co-founder and Head of Business Development will be presenting ‘Amplifying antibody diversity: Single-cell screening combined with immune repertoire sequencing from humanized mice’.
AbCellera’s co-founder and Head of Business Development, Kevin Heyries, Ph.D., will be presenting ‘Amplifying antibody diversity with Single-cell screening and immune repertoire sequencing’.
High throughput single-cell screening is enabling the rapid generation of large, diverse antibody sequence datasets. By combining immune repertoire sequencing with functionally validated single-cell data, we further expand antibody diversity accessible for lead identification. Celium™, AbCellera’s interactive software, interprets these complex datasets using dynamic visual networks to guide the selection of valuable antibodies. This unparalleled ability to both generate and visualize highly curated large datasets dramatically expands the pool of potential therapeutic candidates.
Stefanie Žentelis will be representing AbCellera at the BC Cancer Research Day 2020, hosted by the BC Cancer Graduate Student and Postdoctoral Fellow Society.
Organized by UBC Faculty of Medicine and Vancouver Coastal Health Research Institute, Discovery to Commercialization is a series of education and networking events that aim to raise awareness and knowledge around the therapeutic commercialization process. Lucas Kraft will be representing AbCellera and presenting at the session ‘Building Bridges: How Researchers Came Together During COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19’.
Genome BC presents its 11th Annual Don Rix Distinguished Keynote Address: Battle Lines: Fighting COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19 at the intersection of policy, treatment and prevention. This virtual event brings together the unique perspectives and insights from three BC leaders who have made an indelible impact in the fight against COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19.
Speakers include BC’s Provincial Health Officer, Dr. Bonnie Henry, along with Dr. Mel Krajden, Medical Director at the BC Centre for Disease Control’s Public Health Laboratory and Dr. Carl Hansen, CEO of AbCellera.
Christopher Williamson, Ph.D., Senior Scientist and Project Lead will be presenting “Amplifying Antibody Diversity – Single-Cell Screening Combined with Repertoire Sequencing from Humanized Mice” at the Protein & Antibody Engineering Summit.
Kevin Heyries, Ph.D. will be presenting “From Patient Sample to Antibody Lead in Three Weeks: A Real-Time Response to COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19″ at the virtual Antibody Engineering & Therapeutics U.S.
For more information on AbCellera’s response to COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19, click here.
Bo Barnhart, Ph.D. presented Combating COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days at Antibodies and Vaccines as Drugs for COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19.
Kevin Heyries, Ph.D. will be presenting “From Patient Sample to Antibody Lead in Three Weeks: A Real-Time Response to COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19″ at PepTalk 2021.
For more information on AbCellera’s response to COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19, click here.
Bo Barnhart, Ph.D. will be presenting Combating COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days at Providence Health Care’s Innovation Seminar Series.
Bo Barnhart, Ph.D. will be presenting “From Patient Sample to Antibody Lead in Three Weeks: A Real-Time Response to COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19″ at the Molecular Med Tri-Con in the COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19 Vaccines & Biotherapeutics track.
For more information on AbCellera’s response to COVID-19, click here.
Biocom’s 11th Annual Global Life Science Partnering Conference is an exclusive global partnering forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies.
Carl Hansen, PH.D., CEO of AbCellera will be presenting at LifeSciences BC’s 6th annual Access to Innovation Conference.
Do you have oncology targets in your pipelines? AbCellera is looking forward to connecting with you at the BIO Oncology Virtual Partnering Event.
Looking to accelerate your immunology pipelines? Connect with us at the BIO Immunology Virtual Partnering Event!
Are you in the business of biologics? We look forward to connecting at BIO-Europe Spring.
Christopher Williamson, Ph.D., Senior Research Scientist and Project Lead will be presenting “Amplifying antibody diversity with single-cell screening and immune repertoire sequencing” at the Festival of Biologics USA.
Kevin Heyries, Ph.D., will be presenting “Combating COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days” at the Antibody Engineering & Therapeutics Asia Virtual Scientific Forum.
For more information on AbCellera’s response to COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19, click here.
Stefanie Zentelis, Ph.D., will be presenting “Combating COVIDarchive/capability-pages/cd3/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days” at Biologics Europe: Online.
For more information on AbCellera’s response to COVIDarchive/capability-pages/cd3/-19, click here.
Bo Barnhart, Ph.D., will be presenting will be presenting “Combating COVIDarchive/capability-pages/cd3/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days” at PEGS Boston Virtual.
For more information on AbCellera’s response to COVIDarchive/capability-pages/cd3/-19, click here.
Kevin Heyries, Ph.D., co-founder and Head of Business Development will be hosting a roundtable discussion ‘Next generation antibody discovery platforms—Challenges & Opportunities‘ at the US East Coast Antibody Therapeutics Xchange.
Ester Falconer, Ph.D., Chief Technology Officer, will be participating in a panel discussion on ‘The Promise of Antibody Treatments Across Disease States‘ at SynBioBeta’s first ever BioPharma Day.
Kevin Heyries, Ph.D., will be presenting “Amplifying antibody diversity with single-cell screening and immune repertoire sequencing” at Antibody Engineering & Therapeutics Europe.
Véronique Lecault, Ph.D., Co-founder and Chief Operating Officer, will be participating in a roundtable session discussing how health companies are building, scaling and tackling adoption challenges today in Canada.
Kevin Heyries, Ph.D., cofounder and Head of Business Development will be hosting a roundtable discussion ‘Next generation antibody discovery platforms—Challenges & Opportunities‘ at the US West Coast Antibody Therapeutics Xchange.
Valentine de Puyraimond, MSc, will be presenting “Combating COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days” at Antibody Discovery, Selection and Screening Digital Week.
For more information on AbCellera’s response to COVIDcampaign-pages/bispecifics/archive/capability-pages/cd3/-19, click here
Erica Lovett, Research Scientist at AbCellera, will be presenting “Enduring solutions to the evolving COVIDarchive/capability-pages/cd3/-19 crisis: Discovery of a potent human antibody that neutralizes SARS-CoV-2 and its variants” at Discovery on Target in the Antibodies Against Membrane Protein Targets – Part 2 session on September 29 at 5:55pm EST.
Erica Lovett, Research Scientist at AbCellera, will be presenting “Enduring solutions to the evolving COVIDarchive/capability-pages/cd3/-19 crisis: Discovery of a potent human antibody that neutralizes SARS-CoV-2 and its variants” at PEGS Europe in the Engineering Antibodies stream on November 3rd at 12:40pm CET.
Erica Lovett, Research Scientist at AbCellera, will be presenting “Enduring solutions to the evolving COVIDarchive/capability-pages/cd3/-19 crisis: Discovery of a potent human antibody that neutralizes SARS-CoV-2 and its variants” at Festival of Biologics Europe in the Protein Engineering stream on November 9 at 4:50pm CET.
Roza Bidshahri, Senior Research Scientist and BD Liaison at AbCellera, will be hosting a roundtable discussion on Next Generation Antibody Discovery Platforms – Challenges and Opportunities on November 9 at 11:30am CET.
Roza Bidshari, Ph.D., Senior Research Scientist and BD Liaison, will be hosting a roundtable discussion ‘Next generation antibody discovery platforms—Challenges & Opportunities‘ at the European Antibody Therapeutics Xchange.
Roza Bidshahri, Senior Research Scientist and BD Liaison at AbCellera, will be presenting “Tackling transmembrane targets with Tetrahymena” at Antibody Engineering & Therapeutics on December 13th at 1:45pm PST.
Murray McCutcheon, VP of Corporate Development at AbCellera, will be participating in a fireside chat on Seizing the Opportunity for BC’s Life Sciences Sector at Life Sciences BC’s 7th annual Access to Innovation Conference.
Tim Jacobs, Director of Molecular Design & Engineering at AbCellera, will be presenting “Discover and precision-engineer bispecifics with antibodies from any source using integrated discovery, computational, and engineering technologies” at Festival of Biologics USA on March 9th at 4:50pm PST.
Valentine de Puyraimond, Research Scientist at AbCellera, will be presenting “Keeping Pace with a Pandemic: An Integrated Technology Stack to Discover and Develop Antibody Treatments” at the GRC on Antibody Biology and Engineering.
Bo Barnhart, VP, Translational Research at AbCellera, will be presenting a poster at the AACR Annual Meeting.
AbCellera will be presenting at PEGS Boston on May 3rd at 10am EST in the Difficult-to-Express Proteins track and on May 5 at 9:30am EST in the Engineering Bispecific Antibodies track.
Carl Hansen, CEO, will be participating in a panel discussion on Decentralizing Biotech at MaRS Impact Health.
Murray McCutcheon, VP, Corporate Development at AbCellera, will be participating in a panel discussion on Unlocking Data’s Applications through AI at The Data Effect: How to Build a Digital Society.
AbCellera will be at BIO 2022. Get in touch via the BIO Portal and join our company presentation on June 14 at 11:45am PST in Theater 3 to learn how AbCellera’s antibody discovery technology aims to deliver lead candidates with a higher probability of success, faster.
AbCellera will be presenting at BioProcess International on September 29th at 4:30pm EST in the Manufacturing Strategies & Bioprocessing 4.0 track.
AbCellera will be at BIO-Europe. If you are in the business of biologics, we are looking forward to connecting. Get in touch via the BIO Portal.
AbCellera will be presenting “Discover and precision-engineer cancer bispecifics with integrated discovery, computational, and engineering technologies” at Festival of Biologics Europe on November 2nd at 2:20pm CET.
We will also be hosting a roundtable discussion on Overcomning Challenges in Next Generation Immune Cell Engager Design and Development on November 2nd at 11:30am CET.
AbCellera will be presenting a poster at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Raffi Tonikian, Head of Target Product Profile Integration at AbCellera, will be presenting “Streamline T cell engager discovery with diverse CD3 antibodies and an integrated bispecific engineering platform” at PEGS Europe on November 13th at 12:15pm CET.
AbCellera will be presenting a poster at Antibody Engineering & Therapeutics 2022.
AbCellera will be at the JPM Annual Healthcare Meeting 2023. Join our company presentation on January 11 at 2:15pm PST to learn how AbCellera’s antibody discovery technology aims to deliver lead candidates with a higher probability of success, faster.
AbCellera will be sponsoring the 48th Lorne Conference on Protein Structure & Function.
Raffi Tonikian, Director, Translational Biomarkers, will be presenting “Streamlining T-cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine” at the Keystone Symposia on Multispecific Immune Cell Engagers for Cancer Immunotherapy.
Anne Stevens, AbCellera’s VP of Business Development, will be participating in the panel discussion “Advance your Assets: Strategies for Negotiating and Evaluating Platform Deals” at Fierce’s BD&L Summit on March 14 at 4pm PST.
AbCellera will be presenting a talk on March 21 at 3:40pm PST in the mAbs track at Festival of Biologics 2023.
AbCellera will be presenting two posters at AACR 2023:
– Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies (presented by Bo Barnhart, VP, Translational Research)
See the abstract
– Breaking barriers to access intracellular targets with T-cell engagers: Discovery of diverse, developable, and ultra-specific antibodies against a MAGE-A4 pMHC (presented by Raffi Tonikian, Director, Translational Biomarkers)
See the abstract
AbCellera will be sponsoring the Early Careers Pre-Conference, and presenting two posters at Cell Culture Engineering XVIII.
Véronique Lecault, Director & COO, will be presenting on AbCellera’s pandemic response.
Swapnil Bhargava, SVP, CMC Development and GMP Manufacturing, will be presenting “Streamlining T-cell engager development with diverse, fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine”.
AbCellera will be presenting at PEGS on May 18 at 2:35pm EST in the Engineering Bispecific Antibodies track.
AbCellera will be presenting a poster: Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies at Antibody Engineering & Therapeutics Europe.
Carl Hansen, AbCellera’s co-founder and CEO, will be participating in a panel discussion on Accelerating Drug Development at the Longwood Healthcare Leaders Spring MIT Conference.
AbCellera will be presenting a poster: Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies at Immuno-Oncology Summit Europe.
AbCellera will be sponsoring and attending the 2023 ISPE Biotechnology Conference in Dublin, Ireland. Connect with us to learn about our opportunities in Process Development lab and Clinical Manufacturing.
Andy Clark, Director of Digital Quality, will be presenting on “Undertaking Data Governance to Enable End-to-End Data Capability” at the PDA/FDA Joint Regulatory Conference on September 19th.
Raffi Tonikian, Director of Translational Biomarkers, will be presenting “Adopting a Biomarker-Driven Bispecific Antibody Development” at the World Bispecific Summit.
AbCellera will be presenting at Festival of Biologics Europein Basel, Switzerland.
AbCellera will be presenting two posters at SITC 2023:
– A rational approach for selecting CD3-binding antibodies for T-cell engager development (Abstract #1367)
– Targeting intracellular tumor antigens to fight cancer: Discovery and development of functional and specific T-cell engagers against a MAGE-A4 pMHC (Abstract # 1395)
AbCellera will be presenting at PEGS Europe in Lisbon, Portugal:
Talk
– Selecting optimal antibodies for IND-enabling studies with an integrated high-throughput & lead assessment platform
Posters
– Antibody candidates ready for IND-enabling studies with an integrated antibody discovery and development engine
– Targeting intracellular tumor antigens to fight cancer: Discovery and development of functional and specific T-cell engagers against a MAGE-A4 pMHC
AbCellera is hosting an R&D Day at MassBio.
Join our talk on antibody development against previously intractable targets with Bo Barnhart, Vice President of Translational Research at AbCellera. Attendees can apply themes of how to succeed with more challenging programs to their own pipeline.
See the agenda and register here.
Raffi Tonikian, AbCellera’s Director of Translational Biomarkers, will be presenting the talk “Early integration of biomarker-driven approaches for bispecific development” at DDW’s Cancer Research Summit.
AbCellera will be presenting at Antibody Engineering & Therapeutics USA in San Diego, California.
AbCellera will be at the JPM Annual Healthcare Meeting 2024. Join our company presentation on January 12 at 2:15pm PST to learn how AbCellera is bringing innovative medicines to patients, both by advancing our internal pipeline of programs and partnering with companies that have novel science or innovative technology.
AbCellera will be presenting four posters at AACR 2024:
AbCellera will be presenting on April 16 at 6:10pm PDT at Festival of Biologics 2024.
AbCellera will be presenting at PEGS on May 14, 2024 at 4:30PM ET.
AbCellera will be presenting a poster: Development of PSMA x CD3 T-cell engagers using an integrated, functional approach at Antibody Engineering & Therapeutics Europe 2024.
AbCellera will be presenting a poster: Target-dependent considerations for the design of bispecific T-cell engagers at Immuno-Oncology Summit 2024.
AbCellera will be presenting a poster: Discovery of diverse GPCR-targeted antibodies using integrated technologies at Discovery on Target 2024.
AbCellera will be presenting a poster: Designing T-cell engagers with high potency and low cytokine release at Festival of Biologics Europe 2024.
AbCellera will be presenting a poster: Discovery of diverse GPCR-targeted antibodies using integrated technologies at PEGS 2024.
